– Company Anticipates Part B of MOMENTUM to Serve as Pivotal Study for SRP-5051 and to Seek Accelerated Approval if Successful – Ambulatory and Non-Ambulatory Patients Between the Ages of […]
CureDuchenne Ventures’ early funding of Edgewise in September of 2019 is returning more good news. In November of 2020, Edgewise began its Phase 1 clinical trial on EDG-5506, an experimental […]
June 1, 2021 VISION-DMD 24-week study readout: Update from Santhera Dear U.S. Duchenne community, We are happy to provide an update of the VISION-DMD Phase 2b study conducted by Santhera […]
Results from the first 11 participants enrolled in Study 9001-103 ENDEAVOR showed robust transduction, delivering mean vector genome copies of 3.87 per nucleus Treated patients achieved mean micro-dystrophin expression levels […]
Update on Pfizer’s Duchenne gene therapy Phase 3 clinical program In line with our continued efforts to work with the Duchenne community and share information as it becomes available, we […]
Results suggest a highly potent next-generation treatment that could offer greater efficacy with less frequent dosing SRP-5051 dosed monthly at 30 mg/kg delivered mean exon skipping of 10.79% and mean dystrophin […]
Today, CureDuchenne Ventures is pleased to share that we made a research investment into Code BioTherapeutics and their next-generation gene therapy platform. This is a promising technology aimed at overcoming […]
CureDuchenne continued funding a robust Duchenne drug development pipeline with a new investment in Entrada Therapeutics as part of their latest financing from a group of investors. Entrada Therapeutics’ promising […]
March 15, 2021 CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), […]
